Company: NEWTP
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001587987-25-000141
Chunk: 38

Company: NewtekOne, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
 accordance with ASC 326.

The Company identified 322 and 145 loans as of June 30, 2025 and December 31, 2024, respectively, that did not share similar risk characteristics with the loan segments identified in NOTE 2—SIGNIFICANT ACCOUNTING POLICIES and evaluated them for impairment individually. The following table presents the individually evaluated and collectively evaluated ACL by segment:June 30, 2025December 31, 2024ACLCREC&ISBATotalCREC&ISBATotalIndividually Evaluated$— $809 $11,784 $12,593 $— $— $7,019 $7,019 Collectively Evaluated2,045 731 27,256 30,032 1,430 315 21,469 23,214 Total$2,045 $1,540 $39,040 $42,625 $1,430 $315 $28,488 $30,233 The following table presents the recorded investment in loans individually evaluated and collectively evaluated by segment:June 30, 2025December 31, 2024Recorded InvestmentCREC&ISBATotalCREC&ISBATotalIndividually Evaluated$18,151 $1,265 $36,295 $55,711 $2,635 $— $21,706 $24,341 Collectively Evaluated225,901 50,067 433,973 709,941 189,196 47,558 359,275 596,029 Total$244,052 $51,332 $470,268 $765,652 $191,831 $47,558 $380,981 $620,370 

F-34

The amortized cost basis of loans on nonaccrual status and the individually assessed ACL are as follows:June 30, 2025December 31, 2024Nonaccrual without AllowanceNonaccrual with AllowanceACLNonaccrual without AllowanceNonaccrual with AllowanceACLSBA$10,389 $25,906 $11,784 $7,264 $14,444 $7,019 CRE18,151 — — 2,635 — — C&I— 1,265 809